Bacterial pneumonia and pandemic influenza planning

Emerging Infectious Diseases

Volumn 14, Issue 8, 2008, Pages 1187-1192

  Gupta, Ravindra K ^a   George, Robert ^b   Nguyen Van Tam, Jonathan S ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; GATIFLOXACIN; INFLUENZA VACCINE; LINEZOLID; MACROLIDE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SIALIDASE INHIBITOR; TIGECYCLINE;

BACTERIAL PNEUMONIA; HUMAN; INFLUENZA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PANDEMIC; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT PLANNING; VACCINATION;

ANTI-BACTERIAL AGENTS; DISEASE OUTBREAKS; DRUG RESISTANCE, BACTERIAL; HUMANS; INFLUENZA, HUMAN; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL; POPULATION SURVEILLANCE;

EID: 48749088916     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1407.070751     Document Type: Review

References (33)

1. Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet. 2006;368:2211-8. DOI:10.1016/S0140-6736(06)69895-4
2. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis. 2006;6:303-12. DOI:10.1016/S1473-3099(06)70466-2
3. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006;19:571-82. DOI:10.1128/CMR.00058-05
4. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine. 1999;17(Suppl 1):S3-10. DOI:10.1016/S0264-410-X(99)00099-7
5. Bhat N, Wright JG, Broder KR, Murray EL, Greenberg ME, Glover MJ, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005;353:2559-67. DOI:10.1056/NEJMoa051721
6. Lim WS, Macfarlane JT, Boswell TC, Harrison TG, Rose D, Leinonen M, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001;56:296-301. DOI:10.1136/ thorax.56.4.296
7. Jennings LC, Anderson TP, Beynon KA, Chua A, Laing RT, Werno AM, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax. 2008;63:42-8. DOI:10.1136/thx.2006.075077
8. Juven T, Mertsola J, Waris M, Leinonen M, Meurman O, Roivainen M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J. 2000;19:293-8. DOI:10.1097/00006454-200004000-00006
9. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet. 1987;1:671-4. DOI:10.1016/S0140-6736-(87)90430-2
10. Forgie IM, O'Neill KP, Lloyd-Evans N, Leinonen M, Campbell H, Whittle HC, et al. Etiology of acute lower respiratory tract infections in Gambian children: II. Acute lower respiratory tract infection in children ages one to nine years presenting at the hospital. Pediatr Infect Dis J. 1991;10:42-7.
11. Shann F, Gratten M, Germer S, Linnemann V, Hazlett D, Payne R. Aetiology of pneumonia in children in Goroka Hospital, Papua New Guinea. Lancet. 1984;2:537-41. DOI:10.1016/S0140-6736-(84)90764-5
12. O'Brien KL, Walters MI, Sellman J, Quinlisk P, Regnery H, Schwartz B, et al. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis. 2000;30:784-9. DOI:10.1086/313772
13. Obaro SK, Madhi S. Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining? Lancet Infect Dis. 2006;6:150-61. DOI:10.1016/S1473-3099(06)70411-X
14. Grabowska K, Hogberg L, Penttinen P, Svensson A, Ekdahl K. Occurrence of invasive pneumococcal disease and number of excess cases due to influenza. BMC Infect Dis. 2006;6:58. DOI:10.1186/1471-2334-6-58
15. Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J. 2000;19:1141-7. DOI:10.1097/00006454-200012000-00004
16. Hageman JC, Uyeki TM, Francis JS, Jernigan DB, Wheeler JG, Bridges CB. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006;12:894-9.
17. Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza - Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep. 2007;56:325-9.
18. Goslings WR, Mulder J, Djajadiningrat J, Masurel J. Staphylococcal pneumonia in influenza in relation to antecedent staphylococcal skin infection. Lancet. 1959;2:428-30. DOI:10.1016/S0140-6736-(59)90417-9
19. Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352:1436-44. DOI:10.1056/NEJMoa043252
20. Al-Kaabi N, Solh Z, Pacheco S, Murray L, Gaboury I, Le Saux N. A comparison of group A streptococcus versus Streptococcus pneumoniae pneumonia. Pediatr Infect Dis J. 2006;25:1008-12. DOI:10.1097/01.inf.0000243198. 63255.c1
21. British Infection Society, British Thoracic Society, Health Protection Agency. Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the Department of Health. Thorax. 2007;62(Suppl 1):1-46.
22. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37:1405-33. DOI:10.1086/380488
23. Canadian Pandemic Influenza Plan for the health sector. Annex G, health services: clinical care guidelines and tools, Appendix 5. IV. Antibiotics [cited 2007 Oct 18]. Available from http://www.phacaspc.gc.ca/cpip-pclcpi/pdf-e/16- CPIP-Appendix-G-Clinical_e.pdf
24. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-33. DOI:10.1097/00006454-200102000-00002
25. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667-72. DOI:10.1001/archinte. 163.14.1667
26. Soper GA. The pandemic in the Army camps. JAMA. 1918;71:1899-909.
27. United Kingdom Department of Health, British Thoracic Society, British Infection Society, and Health Protection Agency. Clinical guidelines for patients with an influenza like illness during an influenza pandemic. Version 10.5, Mar 2006 [cited 2007 May 10]. Available from http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4121753
28. Casellas JM, Gilardoni M, Tome G, Goldberg M, Ivanovic S, Orduna M, et al. Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections. J Antimicrob Chemother. 1999;43(Suppl C):37-42. DOI:10.1093/jac/43.suppl_3.37
29. Hayashi K, Kadowaki SE, Takei M, Fukuda H. Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice. Antimicrob Agents Chemother. 2006;50:748-51. DOI:10.1128/AAC.50.2.748-751.2006
30. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-46. DOI:10.1056/NEJMoa022823
31. Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis. 2003;3:71-8. DOI:10.1016/S1473-3099(03)00514-0
32. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341-8. DOI:10.1056/NEJMoa035060
33. Madhi SA, Klugman KP, Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med. 2004;10:811-3. DOI:10.1038/nm1077